huahaipharm(SH:600521)2024-10-09 10:11Financial Performance - The estimated net profit attributable to shareholders for the first three quarters of 2024 is expected to be between 988 million and 1,046 million CNY, representing an increase of approximately 266 million to 324 million CNY, or a year-on-year growth of about 37% to 45%[3] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 990 million and 1,055 million CNY, reflecting an increase of approximately 178 million to 243 million CNY, or a year-on-year growth of about 22% to 30%[3] - The net profit for the same period last year was 721.56 million CNY, and the net profit after deducting non-recurring gains and losses was 811.94 million CNY[5] Factors Contributing to Growth - The significant profit growth is attributed to enhanced sales team dynamics, market penetration, and new business model expansion, leading to increased market share and sales revenue[6] - Continuous optimization of lean management and improved technical capabilities have strengthened cost control and overall competitiveness, contributing to a higher gross margin[6] - The introduction of new products and their gradual market acceptance have further demonstrated effective market expansion results[6] Forecast Accuracy - There are no major uncertainties affecting the accuracy of this performance forecast[7] - The performance forecast data is preliminary and subject to final confirmation in the official Q3 2024 report[7]